Antibody Drug Conjugates

Antibody Drug Conjugates

Traditional cancer treatment consisted of surgery, chemotherapy, and radiation therapy. Over the last two decades, the field of immunooncology has emerged with targeted therapies that target cancer cells by homing in on specific molecular changes in those cells. Radiance Bio, Inc. (“Radiance”) is an immunooncology focussed privately-held biotechnology company which is developing ‘next generation’ Antibody Drug Conjugates (ADCs) that have a better safety profile by reducing the incidence of off-target side effects.

What are Antibody Drug Conjugates?

Unlike chemotherapy, ADCs are designed to target and kill tumor cells while sparing healthy cells and tissues. ADCs comprises a monoclonal antibody or monoclonal antibodies that are directed towards target antigens expressed on the cancer cell surface conjugated to a cytotoxic payload via a chemical linker. This approach reduces systemic exposure to toxic drugs and and therefore toxicity.

ADCs combine the best features of monoclonal antibodies and small molecule drugs and are now amongst the fastest growing drug classes in oncology.

‘Antibody Drug Conjugates are “one of the greatest technologies to battle cancer

Dr. Alberta Bourla, Chairman & CEO, Pfizer’